Business Context and Reporting Period
This Form 6-K filing by Therapix Biosciences Ltd. (not Scisparc Ltd.) covers the month of March 2019, with a specific report date of March 13, 2019. The registrant is a foreign private issuer based in Givatayim, Israel, focused on biotechnology research.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current event disclosure rather than a financial statement.
Material Changes
- Termination of Ramot License: On March 13, 2019, the Company notified Ramot at Tel Aviv University Ltd. of its intent to terminate an exclusive, worldwide research and license agreement entered into in February 2016.
- Subject Matter: The agreement concerned a patent application for methods to treat cognitive decline using low doses of tetrahydrocannabinol.
- Impact Assessment: Management stated that terminating the Agreement is not expected to have a material effect on the Company's operations or business.
Guidance, Outlook, and Risks
The report contains forward-looking statements regarding the termination of the Ramot Agreement and future operations. These statements are subject to risks and uncertainties, including those detailed in the "Risk Factors" section of the Company's Annual Report on Form 20-F filed on April 30, 2018. The Company disclaims any obligation to update these statements.
Investor Verification Checklist
- Verify the exact terms and remaining obligations under the terminated Ramot License Agreement.
- Confirm the Company's current pipeline status regarding cognitive decline treatments post-termination.
- Review the "Risk Factors" in the April 30, 2018 Form 20-F for context on operational uncertainties.
- Check subsequent filings for any updates on the finalization of the termination or unexpected financial impacts.